Weight loss jabs linked to 173 deaths as UK regulators probe deadly risks
By isabelle // 2025-11-17
Copy
 
  • UK regulators report 173 fatal incidents linked to popular weight loss drugs.
  • Deaths span various age groups, including younger adults in their 20s and 30s.
  • Experts warn of inappropriate use by people who are not medically obese.
  • A model was hospitalized after an overdose, illustrating the reckless trend.
  • A British nurse's death certificate officially listed a weight-loss injection as a contributing factor.
You might have seen the headlines celebrating a new era of "miracle" weight loss injections, but a darker story is unfolding behind the scenes. British drug safety regulators are now confronting a grim tally of 173 fatal reports linked to GLP-1 agonist drugs like Ozempic, Mounjaro, and Wegovy. With 52 of those deaths reported since the start of 2024, experts are sounding the alarm that these potent medications are being used recklessly, putting lives at risk for the sake of shedding a few pounds. The data, compiled by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), reveals that the deaths span a wide range of age groups. The victims are not just the elderly or those with advanced illnesses; they include two adults in their 20s, eight in their 30s, 15 in their 40s, and 37 in their 50s. This pattern suggests that the risks associated with these drugs are not confined to a single, high-risk demographic.

A culture of inappropriate use

At the heart of the concern is the growing trend of "inappropriate" use by individuals who are not medically obese. Tam Fry, chair of the National Obesity Forum, issued a stark warning about this phenomenon. "If you take them and you don't need them, and you break the rules, you run the risk of serious complications – or death," Fry stated. He lamented that "Pandora's Box has been opened," with people obtaining the drugs online by lying about their weight. The pursuit of a slimmer figure, often inspired by celebrity culture, is leading many to bypass medical supervision entirely. This was tragically illustrated in September 2024 when Lottie Moss was reportedly rushed to the hospital after an Ozempic overdose. The model, who then weighed just nine stone (126 pounds), suffered violent illness, a seizure, and severe dehydration after taking a jab provided by a friend.

Understanding the official stance

It is crucial to understand the context of these reports. A death reported to the MHRA does not confirm the drug was the cause; it only indicates a reporter’s suspicion. The agency emphasizes that underlying conditions or other medications could be responsible. As MHRA Chief Safety Officer Dr. Alison Cave explained, "It is very important to note that a report with a fatal outcome does not necessarily mean that it was caused by the medicine." The Department of Health and Social Care reiterated that these are "licensed medicines and should only be used under medical supervision by those who are eligible." They are intended as a tool for tackling serious obesity, not as a "quick fix to lose a few pounds."

A history of tragic outcomes

Despite these official cautions, real-world tragedies continue to mount. Susan McGowan, a 58-year-old Scottish nurse, became the first person in Britain whose death was officially linked to a weight-loss jab. Her death certificate listed multiple organ failure, septic shock, and pancreatitis as the cause, with "the use of prescribed tirzepatide" recorded as a contributing factor. She had taken just two low-dose injections of Mounjaro purchased from an online pharmacy. The MHRA’s Yellow Card scheme, established in the wake of the thalidomide scandal, is the mechanism collecting these alarming reports. The data shows that the active ingredient in Ozempic and Wegovy, semaglutide, was linked to 31 fatal reports. Tirzepatide, the powerful component of Mounjaro, was linked to 38. While pharmaceutical companies maintain that patient safety is their top priority, the surge in adverse reports cannot be ignored. The convenience of online access and the powerful allure of rapid weight loss are creating a perfect storm where the known risks are being overshadowed by the promise of results. The conversation around these drugs is a reminder that no pharmaceutical intervention is without potential consequence. In the rush to embrace a modern medical solution to obesity, the fundamental principles of informed consent and rigorous medical oversight are being dangerously diluted. The 173 reported deaths serve as a sobering monument to the price of haste, urging a return to caution and a renewed respect for the powerful nature of these substances. Sources for this article include: DailyMail.co.uk TheSun.co.uk Independent.co.uk Futurism.com
Copy